- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, December 6, 2019
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
An article appearing in Purdue University’s Research Foundation News, titled “An engineering approach to reduce the pain of chemotherapy,” referenced a May 2019 In Focus Blog article published on the website of The American Journal of Managed Care® (AJMC®), titled “Chemotherapy Demand Will Rise Significantly by 2040, and Workforce Will Need to Expand With It.”
Valdosta Daily Times’ article, “Nearly a Quarter of a Million Prescribers Using Surescripts Prescription Price Transparency Tool to View Patient Medication Cost Information,” cited a study published in the January 2006 issue of AJMC®, titled “Varying Pharmacy Benefits With Clinical Status: The Case of Cholesterol-lowering Therapy.” The study stressed the importance of cholesterol-lowering therapy in reducing hospitalizations and emergency department use.
AJMC®’s sister site, The Center for Biosimilars®, was featured in the December 2, 2019, daily regulatory news and intelligence briefing from Regulatory Focus. The article, “Mylan and Biocon Launch Biosimilar Trastuzumab, Ogivri, in the United States,” was included in the section In Focus: US.
A piece by McKnight’s Long-Term Care News referenced a study published in the January 2019 issue of AJMC®: “Mind the Gap: The Potential of Alternative Health Information Exchange.” The study found that open forms of health information exchange selection tools remain critical for comprehensive coverage of patient transitions.
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More
